Endothelial VWF is critical for the pathogenesis of vaso-occlusive episode in a mouse model of sickle cell disease

Proc Natl Acad Sci U S A. 2022 Aug 23;119(34):e2207592119. doi: 10.1073/pnas.2207592119. Epub 2022 Aug 15.

Abstract

Vaso-occlusive episode (VOE) is a common and critical complication of sickle cell disease (SCD). Its pathogenesis is incompletely understood. von Willebrand factor (VWF), a multimeric plasma hemostatic protein synthesized and secreted by endothelial cells and platelets, is increased during a VOE. However, whether and how VWF contributes to the pathogenesis of VOE is not fully understood. In this study, we found increased VWF levels during tumor necrosis factor (TNF)-induced VOE in a humanized mouse model of SCD. Deletion of endothelial VWF decreased hemolysis, vascular occlusion, and organ damage caused by TNF-induced VOE in SCD mice. Moreover, administering ADAMTS13, the VWF-cleaving plasma protease, reduced plasma VWF levels, decreased inflammation and vaso-occlusion, and alleviated organ damage during VOE. These data suggest that promoting VWF cleavage via ADAMTS13 may be an effective treatment for reducing hemolysis, inflammation, and vaso-occlusion during VOE.

Keywords: sickle cell disease; vaso-occlusive episode; von Willebrand factor.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • ADAMTS13 Protein / metabolism
  • ADAMTS13 Protein / pharmacology
  • ADAMTS13 Protein / therapeutic use
  • Anemia, Sickle Cell*
  • Animals
  • Disease Models, Animal
  • Endothelial Cells / metabolism
  • Gene Deletion
  • Hemolysis / drug effects
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Mice
  • Vascular Diseases* / drug therapy
  • Vascular Diseases* / etiology
  • von Willebrand Factor* / genetics
  • von Willebrand Factor* / metabolism

Substances

  • von Willebrand Factor
  • ADAMTS13 Protein